Harry Connick, Jr. and Wife and Cancer Survivor Jill Connick Team Up to Urge People 50 and Older to Get Screened for Colon Cancer
Colon Cancer is Second Leading Cause of Cancer Deaths but Highly Treatable when Caught in Early Stages.
The Exact Sciences team highlighted the enormous strides we’re making toward our mission of eradicating colon cancer when we recently released preliminary fourth quarter and full-year 2017 results. During the year, approximately 571,000 Cologuard tests were completed, a year-over-year increase of 134 percent. Nearly 11,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2017. The total number of providers who have ordered Cologuard since its launch increased to nearly 102,000.
- 11,000 new providers ordered Cologuard during the fourth quarter of 2017
MADISON, Wis., Jan. 7, 2018 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $86.9 million and $87.9 million for the fourth quarter ended Dec. 31, 2017, an increase of 148 percent from the same quarter of 2016. The company completed approximately 176,000 Cologuard tests during the fourth quarter of 2017, 115-percent growth from the same period of 2016.
Topics: Press Releases
With less than a month to go before the start of 2018, let’s check in on the National Colorectal Cancer Roundtable’s (NCCRT) ambitious call to action: “80% by 2018.” Nearly four years ago the organization kicked off this initiative to not only raise awareness of the importance of colorectal cancer screening, but to get more people screened.
For the second year, Exact Sciences earns a place in Deloitte’s Technology Fast 500, an annual list of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. The Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016. Exact Sciences ranked 68 on the list of a total 500 companies.
Cologuard orders generate more than just a colon cancer screening test. The process that supports each test is a system that includes not only the “hardware” needed to provide your sample for screening, but all the information and support needed to ensure every patient can complete the test, receive timely results from their ordering provider, and stay informed every step of the way. We call this our Patient Compliance Program – it results in more patients complying, or following through on their intent to get screened for colon cancer – and it’s proven to be essential to the impact Cologuard is having on getting more people screened.
World-class lab and office space to support demand for Cologuard
- Exact Sciences selects 650 Forward Drive in Madison as site for expanded lab; company also takes ownership of existing office building on site, renamed 1 Exact Lane.
- Campus offers potential to accommodate more than 1,000 employees.
- Combined lab operations will provide Exact Sciences the capacity to deliver more than 4.5 million Cologuard results per year.
Colon Cancer Awareness Month begins with PGA TOUR Champions event
The PGA TOUR and Exact Sciences (NASDAQ: EXAS), the manufacturer of Cologuard, announced today an agreement making the early cancer detection company title sponsor of the PGA TOUR Champions event in Tucson. The Cologuard Classic, named after Exact Sciences’ noninvasive at-home colon cancer screening test, will be contested the week of February 26-March 4, 2018 at Omni Tucson National’s Catalina Course, with a three-year agreement in place through the 2020 season. The Tucson Conquistadores will continue to operate the event.